IDH3A

Across TCGA pan-cancer cohorts, IDH3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IDH3A data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IDH3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IDH3A expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LUAD are the cancer types where IDH3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.507	0.293	.009	16	view →
GBM	DFS	Median	All	0.866	0.637	.002	10	view →
LUAD	OS	Quartile	III,IV	0.723	1.000	.037	3	view →
CCRCC	OS	Tertile	All	0.779	0.960	.040	2	view →
UCEC	OS	Median	All	0.967	0.857	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IDH3A–PDAC (OS)

Open the PDAC breakdown →